Vanguard Personalized Indexing Management LLC Has $1.37 Million Stock Holdings in Qiagen N.V. $QGEN

Key Points

• Vanguard Personalized Indexing Management LLC increased its stake in Qiagen N.V. by 96.3%, holding 28,475 shares valued at $1.37 million as of the latest SEC filing.
• The company reports a net margin of 18.30% and revenue of $533.54 million for the last quarter, which is a 7.7% increase year-over-year.
• Analysts currently rate Qiagen with an average of "Hold" and set a price target of $49.69, despite mixed ratings from different firms.

Vanguard Personalized Indexing Management LLC boosted its stake in Qiagen N.V. (NYSE:QGEN - Free Report) by 96.3% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 28,475 shares of the company's stock after purchasing an additional 13,968 shares during the quarter. Vanguard Personalized Indexing Management LLC's holdings in Qiagen were worth $1,371,000 as of its most recent SEC filing.

A number of other large investors have also bought and sold shares of QGEN. SVB Wealth LLC acquired a new stake in Qiagen in the first quarter worth $31,000. Farther Finance Advisors LLC grew its holdings in Qiagen by 400.5% in the second quarter. Farther Finance Advisors LLC now owns 1,061 shares of the company's stock worth $51,000 after purchasing an additional 849 shares during the period. Hilltop National Bank acquired a new stake in Qiagen in the second quarter worth $66,000. ANTIPODES PARTNERS Ltd acquired a new stake in Qiagen in the first quarter worth $94,000. Finally, GAMMA Investing LLC grew its holdings in Qiagen by 93.9% in the first quarter. GAMMA Investing LLC now owns 2,943 shares of the company's stock worth $118,000 after purchasing an additional 1,425 shares during the period. 70.00% of the stock is currently owned by institutional investors and hedge funds.

Qiagen Stock Up 0.3%

QGEN opened at $48.29 on Friday. The company has a debt-to-equity ratio of 0.25, a current ratio of 1.61 and a quick ratio of 1.35. The company's 50-day moving average is $47.00 and its 200 day moving average is $45.77. Qiagen N.V. has a fifty-two week low of $37.63 and a fifty-two week high of $51.88. The firm has a market capitalization of $10.73 billion, a P/E ratio of 28.53, a PEG ratio of 2.53 and a beta of 0.66.

Qiagen (NYSE:QGEN - Get Free Report) last released its quarterly earnings results on Tuesday, August 5th. The company reported $0.60 earnings per share for the quarter, meeting analysts' consensus estimates of $0.60. Qiagen had a net margin of 18.30% and a return on equity of 14.77%. The company had revenue of $533.54 million for the quarter, compared to analyst estimates of $523.97 million. During the same period last year, the firm earned $0.55 earnings per share. The firm's revenue was up 7.7% on a year-over-year basis. Qiagen has set its Q3 2025 guidance at 0.580- EPS. FY 2025 guidance at 2.350-2.350 EPS. Research analysts expect that Qiagen N.V. will post 2.26 earnings per share for the current fiscal year.

Analysts Set New Price Targets

QGEN has been the subject of a number of research reports. Wall Street Zen cut shares of Qiagen from a "buy" rating to a "hold" rating in a report on Saturday, October 11th. UBS Group raised their price target on shares of Qiagen from $48.00 to $50.00 and gave the stock a "neutral" rating in a report on Thursday, August 7th. Cowen reiterated a "hold" rating on shares of Qiagen in a report on Thursday, August 7th. Bank of America lifted their price objective on shares of Qiagen from $50.00 to $53.00 and gave the company a "buy" rating in a report on Thursday, June 26th. Finally, Weiss Ratings reiterated a "hold (c+)" rating on shares of Qiagen in a report on Wednesday, October 8th. Three equities research analysts have rated the stock with a Buy rating and seven have assigned a Hold rating to the stock. According to data from MarketBeat, the company currently has an average rating of "Hold" and an average target price of $49.69.

Qiagen Company Profile

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials.

Want to see what other hedge funds are holding QGEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Qiagen N.V. (NYSE:QGEN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.